Need Glasses? Try These Italian Digital Eyes Instead
One of the greatest of human pleasures is the ability to see. It is also one of the most vulnerable. It’s no wonder that we have developed eyelids that move at the speed of a reflex. Early on Mother Nature realized eyes are not only important, but very vulnerable as well. Add to their vulnerability the process of aging and you have a set of precious, but precarious tools. Today we have imperfect remedies like glasses, contact lenses, Lasik and cataract surgery. Tomorrow, for the first time, we may have the perfect remedy for shoddy vision in the digital eye.
As reported in Dezeen Magazine, the Italian research studio MHOX recently unveiled a concept to allow people to switch their eyes for digital ones. The technology that makes this possible is 3D printing. MHOX has branded their idea EYE (Enhance Your Eyes.) EYEs will be able to correct blindness, sharpen and filter sight, and connect to Wi-Fi.
Source: Dezeen Magazine
MHOX has been working on the concept for a year but decided to announce their progress after musician Will.i.am’s much publicized statement calling for a more ethical stance towards 3D printing.
Related Story: Electronic eye trial brings hope for blindness cure
Quoted in Dezeen Magazine, the artist said, “"If you can print a liver or a kidney, god dang it, you're going to be able to print a whole freaking person. Now we're getting into a whole new territory. Moses comes down with the 10 commandments and says 'Thou shalt not...'. He didn't say shit about 3D printing."
Source: Dezeen Magazine
Specifically, MHOX’s vision entails removing the original eye first. Then installing an organic component called a deck. The deck would function as the connection point between the brain and the EYE.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.